Our partners in Europe!
We collaborate with a wide range of organizations to draw on their expertise and to ensure the highest coordination in development efforts. These partnerships help us reach our goals and desired targets with the necessary support, while boosting the efficiency and effectiveness of development aid.
The involved Department is the R&D one that was established in 2018 specializing in research funding in health and social matters in collaborative competitive calls at EU and international levels. We participate, both as coordinator and partner, in several research projects funded by the European Union such as HORIZON 2020, ERASMUS+ and EEA Grants, the Cyprus Research Promotion Foundation and other sources.
GATEKEEPER is a European Multi Centric Large Scale Pilot on Smart Living Environments, with 42 European partners and nine pilots across seven countries. The main objective is to enable the creation of a platform that connects healthcare providers, businesses, entrepreneurs, and elderly citizens and the communities they live in, ensuring healthier independent lives for the ageing population. This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement Nº 857223.
The project is described at: www.gatekeeper-project.eu
Although artificial intelligence (AI) and machine learning (ML) provide unprecedented opportunities for improved cancer detection, various technical challenges as well as a lack of data availability hamper their utilisation. The EU-funded INCISIVE project aims to develop a toolbox for enhancing the accuracy, specificity and sensitivity of existing cancer imaging methods. The idea is to generate a pan-European repository of medical images that can be used for ML-based training for various types of cancer. The project’s deliverables will assist the accurate prediction of tumour spread, evolution and relapse, in addition to helping stratify patients.
EUROPEAN FAIR PRICING NETWORK (EFPN)
PASYKAF is launching a European collaboration collective which aims to put an end to expensive cancer drugs. Patients must be given better access to new drugs by directly linking research conducted into the price and availability of cancer drugs in several European countries to lobbying. This is the very first time this problem is being tackled on this scale. PASYKAF has taken on a pioneering role in Europe with the establishment of this collective.
The European Fair Pricing Network (EFPN) strives for fair and clear pricing and a transparent market for new and expensive cancer drugs. The EFPN was founded by PASYKAF and other European cancer organisations from more than 10 different countries.
The European Fair Pricing Network (EFPN) aims to achieve fair prices for cancer medicines and, more broadly, works towards a pharmaceutical market which produces accessible and truly innovative medicines for patients.